New Study Indicates Quinolone Antibiotics As Main Cause C. Diff Epidemic

A Study recently published in the journal The Lancet Infectious Diseases indicates that overuse of fluoroquinolones may be sole cause of deadly C. Diff Epidemic. Antibiotic overuse can have severe consequences, especially with certain types of antibiotics and this study begins to quantify one of the ways in which this happens and how widespread the harm […]

By |February 16th, 2017|General News|0 Comments

Canadian National Health Service Safety Review Identifies Serious Quinolone Risks

On January 23, 2017 the national health service of Canada, Health Canada, announced that their recent safety review revealed serious safety issues with fluoroquinolone antibiotics. This follows the 2015 review conducted by the U.S Food & Drug Administration which reached a similar conclusion. The FDA review results were announced on 5/12/2016. In addition to […]

By |January 28th, 2017|General News|0 Comments

New Fluoroquinolone Formulation in Development

Pulmaquin, an inhaled liposomal ciprofloxacin, is currently undergoing two Phase 3 clinical studies to determine its safety and effectiveness as an inhaled formulation for the treatment of patients with non-cystic fibrosis bronchiectasis, cystic fibrosis or non-tuberculous mycobacteria.

Changing the Tide of Antibiotic-Resistant Infections

By |January 15th, 2017|General News|0 Comments

The Quinolone Vigilance Foundation 2016 Year in Review

The Quinolone Vigilance Foundation wishes to thank all of our supporters. We had a busy and productive year and we would not be able to do this kind of work without all of our supporters. The Year in Review is posted on our Facebook page: https://www.facebook.com/notes/quinolone-vigilance-foundation/2016-year-in-review/1332337300118474

QVF Testifies at FDA Hearing about off-label use of medications and devices

The Quinolone Vigilance Foundation testified at the FDA and made a presentation on behalf of QVF and the USA Patient Network at the FDA Meeting on Off Label Uses of drugs and devices.

Many patients are given prescription drugs and devices for uses that are not approved by the FDA (called “off label”) without informed […]

By |November 10th, 2016|General News|0 Comments

Melinta Therapeutics Submits Baxdela (delafloxacin) New Drug Application for Hospital-Treated Skin Infections

Melinta Therapeutics announced on October 24, 2016 that it has submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for approval of IV and oral Baxdela™ (delafloxacin) for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI).

Melinta Therapeutics Press Release

By |October 24th, 2016|General News|0 Comments

Patient advocacy group warning doctors of dangerous drugs, label changes

WRIC-TV airs news story about QVF’s Dear Healthcare Provider letter campaign. QVF Executive Director Rachel Brummert and QVF Ambassador Jonathan Furman sat down with WRIC-TV investigative reporter Kerri O’Brien on October 13.

By |October 20th, 2016|General News|0 Comments

The Quinolone Vigilance Foundation launches new research initiative

The Quinolone Vigilance Foundation has been working for several months on a new research initiative, and finalized it on October 13, 2016. QVF is partnering with a major university to collect and analyze quinolone related data. We are not naming the university at this time to protect the integrity of the project. Once the […]

By |October 13th, 2016|General News|0 Comments

QVF & Progressive Medical Center Release PSA Video

The Quinolone Vigilance Foundation and Progressive Medical Center have collaborated to produce and release a short educational video about issues surrounding quinolone antibiotics.

Part one (2:59 mins)-

Part two (4:38 mins)-

By |September 23rd, 2016|General News|0 Comments

QVF Letter Writing Campaign–Please Help Us Educate on Recent Drug Safety Information from the FDA

We have some news to share with everyone.

It would be preferable if the FDA were more effective in communicating emerging information about drug safety issues. Sadly, the FDA never sent out Dear Doctor letters on the recent acknowledgement of fluoroquinolone risks, and despite working to try to get the FDA to send them, the […]

By |September 16th, 2016|General News|0 Comments